WordNet

any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 抗原提示細胞 antigen presenting cells
2. BおよびTリンパ球の正常な発生 normal b and t lymphocyte development
3. 体液性免疫応答 the humoral immune response
4. 古典型ホジキンリンパ腫の疫学、病理学的特徴、および診断 epidemiology pathologic features and diagnosis of classical hodgkin lymphoma
5. 慢性リンパ性白血病の臨床症状、病理学的特徴、診断、および鑑別診断 clinical presentation pathologic features diagnosis and differential diagnosis of chronic lymphocytic leukemia

Redman JM1, Hill EM1, AlDeghaither D1, Weiner LM2.
Molecular immunology.Mol Immunol.2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23.
The therapeutic utility of antibodies and their derivatives is achieved by various means. The FDA has approved several targeted antibodies that disrupt signaling of various growth factor receptors for the treatment of a number of cancers. Rituximab, and other anti-CD20 monoclonal antibodies are acti
PMID 25911943

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

Shor B1, Gerber HP2, Sapra P3.
Molecular immunology.Mol Immunol.2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7.
Calicheamicin is a DNA-damaging agent that, following intracellular activation, binds to DNA in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and subsequent cell death. Importantly, the mechanism of action of calicheamicin is fundamentally different from the tubuli
PMID 25304309

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

Piccione EC1, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R.
mAbs.MAbs.2015 Sep 3;7(5):946-56. doi: 10.1080/19420862.2015.1062192.
Agents that block the anti-phagocytic signal CD47 can synergize with pro-phagocytic anti-tumor antigen antibodies to potently eliminate tumors. While CD47 is overexpressed on cancer cells, its expression in many normal tissues may create an 'antigen sink' that could minimize the therapeutic efficacy
PMID 26083076